



COPY OF PAPERS  
ORIGINALLY FILED

2

Attorney Docket No.: QUIG-1006USCIP1

RECEIVED

MAY 23 2002

REMARKS

TECH CENTER 1300/2900

Claims 1-37 are currently pending in the present application.


The specification has been amended to insert a reference to the parent application in order to comply with the requirements of 35 U.S.C. §120 for claiming the benefit of an earlier-filed U.S. patent application.

In response to the Office Action dated April 23, 2002, Applicant provisionally elects Group I, claims 1-20, for initial examination on the merits with traverse.

In support of the restriction requirement, the Examiner alleges that the process as claimed in claims 1-2 can be practiced with another materially different product, alleging that interleukin-1- $\alpha$  derivatives can be used in the method claimed in claims 1-20. The applicant traverses the requirement on the basis that claims 1-20 specifically require the use of the composition of claims 21-37 in the method of claims 1-20. Accordingly, interleukin-1- $\alpha$  derivatives cannot be used in the process, as claimed, since the process, as claimed, requires the use of the composition of claims 21-37.

Favorable consideration and withdrawal of the restriction requirement is requested. A speedy and favorable first Office Action on merit is respectfully solicited.

Respectfully submitted,

  
Kevin J. Dunleavy  
Registration No. 32,024

Dated: May 9, 2002

KNOBLE & YOSHIDA, LLC (Customer No. 21,302)  
Eight Penn Center, Suite 1350  
1628 John F. Kennedy Blvd.  
Philadelphia, PA 19103  
Direct Dial No.: (215) 599-0606  
Facsimile No.: (215) 599-0601  
e-mail: kjdunleavy@patentwise.com